Measles

• NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US).
• Health-state occupancy probabilities and key model inputs were based on the individual patient-level data from NefIgArd, the Phase 3 randomized controlled trial evaluating Nefecon.
• Andrew Udell, president, North America at Calliditas stated: “These findings are timely and relevant in light of the 2-year eGFR results from the NefIgArd trial we recently announced.
• Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

• These illnesses, from the common cold to pneumonia, have been a plague on mankind throughout history.
• Most are caused by viruses, so if you’ve ever been told “you probably have a virus” by a clinician, they were likely correct.
• Respiratory infections are the leading cause of death in children under 5 globally and a major reason for hospitalization of children in developed countries.
• As a pediatric infectious disease specialist and virologist, I have led my team in HMPV research for over 20 years, and I’ve personally cared for many children with this infection.

Origins of human metapneumovirus

• The human metapneumovirus was isolated from people with acute respiratory infection and sequenced in 2001 using a combination of specialized culture and molecular techniques.
• Third, genetic analysis by several different groups shows that the closest recent ancestor of HMPV is a bird virus, avian metapneumovirus.
• Evolutionary and genetic analysis suggests that the human virus diverged from the bird virus several hundred years ago.

HMPV in children

• Initial research groups focused on children and quickly discovered that HMPV caused respiratory infections in children worldwide, including Canada, Australia, Japan, Hong Kong, South Africa and Argentina.
• Indeed, HMPV is a common cause of acute respiratory disease in children in every country examined, and most children get the infection for the first time by age 5.
• Children with underlying risk factors, such as those born prematurely and those with conditions like asthma,
  or those who have compromised immune systems, such as organ transplant recipients or children being treated for cancer, are at higher risk for severe HMPV.

Not just for kids

• This is especially true in adults over 65 years old, or those with underlying conditions.
• HMPV and RSV were more common than the flu in people 65 and older, presumably because many were vaccinated against the flu.
• Another national study of adults hospitalized for pneumonia showed that HMPV was as common as RSV, and nearly as common as influenza.

Why HMPV is still so underrecognized

• Despite being a common cause of serious respiratory disease, HMPV remains underdiagnosed by clinicians and little recognized by the general population.
• Most people with an acute respiratory illness don’t get any testing, and if they do, only complex molecular testing can detect HMPV.
• But HMPV circulates predictably every year, and in North America the peak is typically February through May.

A dearth of treatments

• Right now, there are no specific antiviral drugs to treat HMPV as there are for flu and COVID-19.
• As with the many other respiratory viruses that cause colds, most infected people will do just fine with rest and fluids.

• SEATTLE, March 8, 2023 /PRNewswire/ -- " Antimicrobial Coatings Market " is the title of a new report from Data Bridge Market Research.
• Key growth strategies, drivers, opportunities, key segment, Porter's Five Forces analysis, and competitive environment are all dissected in detail in the research.
• Antimicrobial Coatings market analysis report offers meticulous investigation of current scenario of the global market, which considers numerous market dynamics.
• The report identifies and analyses the rising trends along with key drivers, challenges and opportunities in the Antimicrobial Coatings industry.

• These data suggest UPLIZNA does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies.
• In total, the analysis found a low incidence rate of infections (0.024 events per patient year) among UPLIZNA-treated patients.
• Of the 10 patients with known outcomes, six were reported as “recovered/resolved,” two as not recovered/resolved and two patients died.
• “The results of these analyses provide further support that UPLIZNA is an effective long-term treatment for NMOSD with a favorable safety profile.”